- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
AcelRx Pharmaceuticals Inc
+ Add to WatchlistACRX:US
7.4500 USD 0.1900 2.62%As of 17:20:00 ET on 05/23/2013.
Snapshot for AcelRx Pharmaceuticals Inc (ACRX)
| Open: | 7.2600 | Day's Range: | 6.8000 - 7.6499 | Volume: | 643,044 |
|---|---|---|---|---|---|
| Previous Close: | 7.2600 | 52wk Range: | 2.2700 - 7.6499 | 1-Yr Rtn: | +115.94% |
Key Statistics for ACRX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -1.4800 |
| Est. EPS (USD) (12/2013) | -0.9600 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 277.42 |
| Shares Outstanding (M) | 37.24 |
| 30 Day Average Volume | 384,854 |
| Price/Book (mrq) | 8.1561 |
| Price/Sale (ttm) | 68.3682 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/09/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ACRX
Company Profile & Key Executives for ACRX
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The Company's solutions are designed to provide mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.
| Adrian AdamsChairman | Richard A KingPresident/CEO |
| James H Welch "Jim"Chief Financial Officer | Pamela P PalmerChief Medical Officer/Co-Founder |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ACRX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page